Disease-Modifying Therapies, Outcomes, Risk Factors and Severity of COVID-19 in Multiple Sclerosis: A MENACTRIMS Registry Based Study

BACKGROUND: Multiple sclerosis (MS) patients have been considered a higher-risk population for COVID-19 due to the high prevalence of disability and disease-modifying therapy use; however, there is little data in our Middle East and North Africa region (MENA) identifying clinical characteristics of...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeineddine, Maya, Boumediene, Farid, Al-Hajje, Amal, Salameh, Pascale, Massouh, Joelle, Saab, Georges, Al-Roughani, Raed, Al-Mahdawi, Akram, Shalaby, Nevin, Inshasi, Jihad, Sahraian, Mohamad Ali, Gouider, Riadh, Mrabet, Saloua, Al-Khabouri, Jaber, Shaygannejad, Vahid, Chentouf, Amina, Yamout, Bassem
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier B.V. 2023
Materias:
Msc2022-a-2170
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10065155/
http://dx.doi.org/10.1016/j.msard.2022.104369

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10065155/
http://dx.doi.org/10.1016/j.msard.2022.104369

Ejemplares similares